Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Plus Therapeutics Inc PSTV
$3.87
▲ +6.03%
(+$0.22)
⬆️ Above Yest. High
🗓️ Earnings Next Week
Open
$3.65
Prev Close
$3.65
Day Range
$3.62 – $3.95
52W Range
$2.90 – $23.43
Market Cap
$26.64M
Beta
1.48
EPS (TTM)
$-2.50
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2000-08-09 |
| Shares Out. | 6,880,000 |
| Website | plustherapeutics.com/ ↗ |
| Phone | 13026365440 |
| Employees | 28 |
| Revenue | $1.0M |
| Gross Profit | $1.0M |
| Net Income | -$6.9M |
| Free Cash Flow | -$21.7M |
| Total Assets | $19.9M |
| Total Liabilities | $8.0M |
| Equity | $12.0M |
About Plus Therapeutics Inc
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Plus Therapeutics Inc is a publicly traded company under the ticker symbol PSTV on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)